EU Commission finds drugmakers blocked generics; anti-trust action may follow

8 December 2008

Following investigations which started early this year Marketletter January 21), the European Commission has now published its preliminary report on the competition inquiry into the pharmaceutical sector, which finds that in this industry it does not work as well as it should. Although not naming specific companies in its report, it is known that raids by EC officials on drugmakers' premises relating to this project included majors such as Pfizer, GlaxoSmithKline and Sanofi-Aventis, and anti-trust action could be instigated against some.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight